These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 34571322)
1. Recent advances in therapeutic nucleic acids and their analytical methods. Talap J; Zhao J; Shen M; Song Z; Zhou H; Kang Y; Sun L; Yu L; Zeng S; Cai S J Pharm Biomed Anal; 2021 Nov; 206():114368. PubMed ID: 34571322 [TBL] [Abstract][Full Text] [Related]
2. Analysis of therapeutic nucleic acids by capillary electrophoresis. Wei B; Goyon A; Zhang K J Pharm Biomed Anal; 2022 Sep; 219():114928. PubMed ID: 35853263 [TBL] [Abstract][Full Text] [Related]
3. Re-Engineering RNA Molecules into Therapeutic Agents. Egli M; Manoharan M Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917 [TBL] [Abstract][Full Text] [Related]
4. Insights from crystallographic studies into the structural and pairing properties of nucleic acid analogs and chemically modified DNA and RNA oligonucleotides. Egli M; Pallan PS Annu Rev Biophys Biomol Struct; 2007; 36():281-305. PubMed ID: 17288535 [TBL] [Abstract][Full Text] [Related]
5. Capillary gel electrophoresis and antisense therapeutics. Analysis of DNA analogs. DeDionisio LA; Lloyd DH J Chromatogr A; 1996 May; 735(1-2):191-208. PubMed ID: 8767742 [TBL] [Abstract][Full Text] [Related]
6. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. Landmesser U; Poller W; Tsimikas S; Most P; Paneni F; Lüscher TF Eur Heart J; 2020 Oct; 41(40):3884-3899. PubMed ID: 32350510 [TBL] [Abstract][Full Text] [Related]
7. Characterization of therapeutic oligonucleotides by liquid chromatography. Goyon A; Yehl P; Zhang K J Pharm Biomed Anal; 2020 Apr; 182():113105. PubMed ID: 32004766 [TBL] [Abstract][Full Text] [Related]
8. RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Bajan S; Hutvagner G Cells; 2020 Jan; 9(1):. PubMed ID: 31936122 [TBL] [Abstract][Full Text] [Related]
9. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]
11. An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics. Ingle RG; Fang WJ Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111643 [TBL] [Abstract][Full Text] [Related]
12. Delivery of nucleic acid therapeutics for cancer immunotherapy. Zhou S; Chen W; Cole J; Zhu G Med Drug Discov; 2020 Jun; 6():. PubMed ID: 34337382 [TBL] [Abstract][Full Text] [Related]
13. Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. Colombo S; Zeng X; Ragelle H; Foged C Expert Opin Drug Deliv; 2014 Sep; 11(9):1481-95. PubMed ID: 24950005 [TBL] [Abstract][Full Text] [Related]
14. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. Dhuri K; Bechtold C; Quijano E; Pham H; Gupta A; Vikram A; Bahal R J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604776 [TBL] [Abstract][Full Text] [Related]
15. Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes. Vetter VC; Wagner E J Control Release; 2022 Jun; 346():110-135. PubMed ID: 35436520 [TBL] [Abstract][Full Text] [Related]